

## Tomuzotuximab

Cat. No.:	HY-P99324
CAS No.:	1646321-00-7
Target:	EGFR; Apoptosis
Pathway:	JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Apoptosis
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

<b>Description</b>	Tomuzotuximab (Anti-Human EGFR Recombinant Antibody) is a fully human glycoengineered IgG1 monoclonal antibody against EGFR. Tomuzotuximab has anticancer effects <sup>[1]</sup> .
<b>In Vitro</b>	Tomuzotuximab has a fully human glycosylation pattern and is glyco-optimised at its Fc domain, while fully retaining the affinity, specificity, EGFR inhibition and induction of apoptosis of Cetuximab <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Waer Fiedler, et al. Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. ESMO Open. 2018 Feb 1;3(2):e000303.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA